Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF 91 Receivables Turnover is 2.87 as of Dec. 2025. GuruFocus rates MEDGF with a GF Score™ of 91/100 and a GF Value™ of $100.71. The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Medacta Group ranks better than 55.54% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medacta Group's Revenue for the
six
months ended in Dec. 2025 was $397.8 Mil. Medacta Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was $138.7 Mil.
Hence, Medacta Group's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.87.
Medacta Group (OTCPK:MEDGF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medacta Group Receivables Turnover Related Terms
Medacta Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Medacta Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDGF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Medacta Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medacta Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (MEDGF) has a Receivables Turnover of 2.87 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #361 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is Medacta Group's Receivables Turnover too high?
Medacta Group's current Receivables Turnover is 2.87. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Medacta Group's value of 2.87 is 47.9% below this industry median. Based on the distribution chart, Medacta Group ranks #361 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #361 out of 812 companies for Receivables Turnover. This puts Medacta Group in the upper half of its industry. The industry median Receivables Turnover is 5.51. Medacta Group's value of 2.87 is 47.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current Receivables Turnover of 2.87 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Receivables Turnover is 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Medacta Group (MEDGF) has a current Receivables Turnover of 2.87. The stock's GF Value™ is $100.71, compared to a current price of $83.91 — trading 16.7% below its estimated fair value. The current Receivables Turnover is 2.87 and 47.9% below the Medical Devices & Instruments industry median of 5.51. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medacta Group (MEDGF), the current Receivables Turnover is 2.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of $83.91 is trading 16.7% below its estimated GF Value™ of $100.71.
Key valuation signals for MEDGF:
Receivables Turnover: 2.87
GF Value™: $100.71 vs. price of $83.91 (16.7% below fair value)
Industry Position: 47.9% below the Medical Devices & Instruments median (#361 of 812)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for MEDGF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
